Vital Signs: J&J's bid for Tremfya expansion takes on patient preferences and payer challenges – FirstWord Pharma

1. Vital Signs: J&J’s bid for Tremfya expansion takes on patient preferences and payer challenges  FirstWord Pharma
2. Guselkumab Subcutaneous Induction Advances Ulcerative Colitis Care, With David Rubin, MD  HCPLive
3. Subcutaneous Formulation of Guselkumab Receives FDA Approval in Ulcerative Colitis  Pharmacy Times
4. Guselkumab receives CHMP backing for subcutaneous induction in ulcerative colitis  PharmaTimes
5. J&J’s TREMFYA wins FDA approval for subcutaneous ulcerative colitis treatment  StreetInsider

Continue Reading